# Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects

> **NCT05118516** · PHASE1 · COMPLETED · sponsor: **Gannex Pharma Co., Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** ASC43F

## Key facts

- **NCT ID:** NCT05118516
- **Lead sponsor:** Gannex Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-01
- **Primary completion:** 2021-12-07
- **Final completion:** 2021-12-07
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05118516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05118516, "Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05118516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*